# GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma

> **NCT07209813** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Gene Key Life Technology Co., Ltd** · enrollment: 48 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** GKL-006

## Key facts

- **NCT ID:** NCT07209813
- **Lead sponsor:** Beijing Gene Key Life Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-12
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07209813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07209813, "GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07209813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*